Published on October 29, 2009 at 3:52 AM
Drug discovery company SCYNEXIS, Inc. today announced that supportive data from a preclinical study of the Company’s lead product candidate for hepatitis C (HCV), SCY-635, will be presented in a poster session at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) being held in Boston, MA, October 30-November 3, 2009. SCYNEXIS plans to initiate a Phase 2a combination trial of SCY-635 in patients with HCV in the second quarter of 2010. SCY-635 is a non-immunosuppressive cyclosporin analog that has demonstrated potent suppression of plasma viremia when given as monotherapy to adults with chronic hepatitis C virus infection.
Presentation at AASLD:
Tuesday, November 3, 8:00 AM – 1:00 PM ET: HCV Therapy: Preclinical and Clinical Development Session
Abstract 1595 entitled “Antiviral Activity of the Non-Immunosuppressive Cyclophilin Inhibitor SCY-635 in Combination with Investigational and Approved Anti-HCV Agents” will be presented by SCYNEXIS. In preparation for the Phase 2a clinical trial, the in vitro antiviral activity of SCY-635 was evaluated in multiple two-drug combinations in this preclinical study. The activity of SCY-635 was investigated in combination with non-nucleoside polymerase inhibitors, nucleoside polymerase inhibitors, protease inhibitors (boceprevir, telaprevir), ribavirin and interferon alpha 2b.
http://www.scynexis.com/